Literature DB >> 19380411

Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Rodney J Hicks1.   

Abstract

Despite recognized limitations, structural imaging with CT remains the standard technique for evaluating the response of lung cancer to both chemotherapy and radiotherapy. This evaluation has become increasingly important with the advent of neoadjuvant therapy before surgery. The high uptake of (18)F-FDG in most lung cancers and the demonstration that successful treatment reduces uptake have led to increasing enthusiasm for the use of PET and PET/CT to assess the therapeutic response. In this review, theoretic considerations and current evidence supporting the role of (18)F-FDG PET are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380411     DOI: 10.2967/jnumed.108.057216

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  51 in total

1.  A comparison study of dual-energy spectral CT and 18F-FDG PET/CT in primary tumors and lymph nodes of lung cancer.

Authors:  Osman Kupik; Yavuz Metin; Gülnihan Eren; Nurgul Orhan Metin; Medeni Arpa
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

Review 2.  Computerized PET/CT image analysis in the evaluation of tumour response to therapy.

Authors:  W Lu; J Wang; H H Zhang
Journal:  Br J Radiol       Date:  2015-02-27       Impact factor: 3.039

Review 3.  Multiplexed imaging in cancer diagnosis: applications and future advances.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Mikako Ogawa; Peter L Choyke; Satomi Kawamoto
Journal:  Lancet Oncol       Date:  2010-03-24       Impact factor: 41.316

Review 4.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

5.  Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.

Authors:  Benjamin Houdu; Charline Lasnon; Idlir Licaj; Guy Thomas; Pascal Do; Anne-Valerie Guizard; Cédric Desmonts; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-14       Impact factor: 9.236

Review 6.  Clinical applications of textural analysis in non-small cell lung cancer.

Authors:  Iain Phillips; Mazhar Ajaz; Veni Ezhil; Vineet Prakash; Sheaka Alobaidli; Sarah J McQuaid; Christopher South; James Scuffham; Andrew Nisbet; Philip Evans
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

7.  Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.

Authors:  Tomonobu Koizumi; Toshirou Fukushima; Daisuke Gomi; Takashi Kobayashi; Nodoka Sekiguchi; Keiko Mamiya; Kazunari Tateishi; Akane Katou; Kazuhiro Oguchi
Journal:  Med Oncol       Date:  2017-09-01       Impact factor: 3.064

Review 8.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

9.  The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).

Authors:  Odré Palie; Pierre Michel; Jean-François Ménard; Caroline Rousseau; Emmanuel Rio; Boumédiene Bridji; Ahmed Benyoucef; Marc-Etienne Meyer; Khadija Jalali; Stéphane Bardet; Che Mabubu M'vondo; Pierre Olivier; Guillaume Faure; Emmanuel Itti; Christian Diana; Claire Houzard; Françoise Mornex; Frederic Di Fiore; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-29       Impact factor: 9.236

Review 10.  RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.

Authors:  Els L van Persijn van Meerten; Hans Gelderblom; Johan L Bloem
Journal:  Eur Radiol       Date:  2009-12-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.